What do systematic reviews say?

Chemotherapy with TKI vs chemotherapy alone

Chemotherapy with TKI showed no clear difference in quality of life (QoL) compared with chemotherapy alone (low certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 164 participants
  Low

Bevacizumab plus chemotherapy vs chemotherapy alone

The review found no eligible studies for this question.

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1638 participants
  Very low

Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone

The review found no eligible studies for this question.

• Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

TG4010 added to chemotherapy vs chemotherapy alone

The review found no eligible studies for this question.

• Therapeutic vaccines for advanced non‐small cell lung cancer 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Hysterectomy (radical) with neoadjuvant chemotherapy vs chemoradiotherapy alone

The review found no eligible studies for this question.

• Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 146 participants
  Low

Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 315 participants
  Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1340 participants
  Moderate

Hysterectomy (simple or radical) with neoadjuvant chemotherapy vs Radiotherapy alone

The review found no eligible studies for this question.

• Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 486 participants
  Low

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 890 participants
  High

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 744 participants
  Moderate

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

The review found no eligible studies for this question.

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table (subcomparison 3): chemotherapy agent(s) plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  450 participants
  Very low

Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1870 participants
  Very low

Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1772 participants
  Very low

Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 156 participants
  Very low

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone

The review found no eligible studies for this question.

• Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings 1: PLD with chemotherapy vs PLD alone

The review found no eligible studies for this question.

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found